Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P83110

UPID:
HTRA3_HUMAN

ALTERNATIVE NAMES:
High-temperature requirement factor A3; Pregnancy-related serine protease

ALTERNATIVE UPACC:
P83110; Q7Z7A2

BACKGROUND:
The Serine protease HTRA3, recognized by its alternative names High-temperature requirement factor A3 and Pregnancy-related serine protease, is integral to the cleavage of key components in the extracellular matrix such as beta-casein/CSN2, decorin/DCN, biglycan/BGN, and fibronectin/FN1. By potentially inhibiting TGF-beta signaling through ECM proteoglycan degradation, HTRA3 may indirectly suppress tumor growth. Additionally, it plays a critical role in placental development by regulating trophoblast invasion, and is involved in ovarian development and the differentiation of granulosa cells.

THERAPEUTIC SIGNIFICANCE:
The exploration of Serine protease HTRA3's functions offers promising avenues for therapeutic intervention. Its critical roles in tumor suppression, placental development, and ovarian function underscore its potential as a target in the development of innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.